glp 1 chronic kidney disease Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis GLP-1 RAs, Other Agents, Underused

They found that GLP-1 users experienced chronic cough approximately 29% more often than patients taking alternatives such as DPP-4 inhibitors, SGLT2 inhibitors, and sulfonylureas

Karl Nadolsky, endocrinologist and diplomate at the American Board of Obesity Medicine

GLP-1 drugs' potential use in preventing or controlling cancer was a major theme among the research presented by the American Society of Clinical Oncology at its recent meeting

Our comprehensive approach includes advanced treatments like compounded Semaglutide and Tirzepatide, helping patients achieve 15-20% body weight reduction

[DOI] [PMC free article] [PubMed] [Google Scholar] 107.The Glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome